Therapeutic vascularization in regenerative medicine

Area of Science:

• Biomedical Engineering
• Molecular Biology
• Regenerative Medicine

Background:

• Therapeutic angiogenesis is crucial for tissue engineering and treating ischemic diseases.
• Vascular endothelial growth factor (VEGF) drives new blood vessel formation but requires controlled delivery.
• Uncontrolled VEGF expression can cause harmful vascular tumors and unstable vessel growth.

Purpose of the Study:

• To review the biology of VEGF and angiogenesis.
• To discuss therapeutic strategies for controlled VEGF delivery.
• To explore mechanisms regulating vessel stabilization and aberrant growth.

Main Methods:

• Overview of VEGF and angiogenesis biology.
• Discussion of gene therapy, genetically modified progenitors, and ECM engineering.
• Presentation of recent insights into vessel stabilization and growth regulation.

Main Results:

• Precise control of VEGF dose and duration is essential for therapeutic efficacy.
• VEGF delivery must consider local microenvironment concentration due to ECM binding.
• Short-term VEGF expression (<4 weeks) results in vessel regression.

Conclusions:

• Optimizing VEGF delivery strategies is key to safe and effective therapeutic angiogenesis.
• Understanding vessel stabilization mechanisms can identify targets to prevent aberrant vascularization.
• Novel molecular targets are needed to improve the safety and efficacy of angiogenic therapies.